Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 10;5(1):e2013024.
doi: 10.4084/MJHID.2013.024. Print 2013.

Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens

Salah Abbasi  1 , Faten Maleha, Muhannad Shobaki
Affiliations

Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens

Salah Abbasi et al. Mediterr J Hematol Infect Dis. .

Abstract

Objectives: Accurate data about adult acute lymphoblastic leukemia (ALL) are lacking. We aim to assess demographics, prognostic factors, and outcome of ALL therapy at King Hussein Cancer Center (KHCC) in Jordan, and to compare the efficacy of two protocols.

Methods: We reviewed medical records of adults diagnosed and treated for ALL at KHCC from January, 2007 to December, 2011.

Results: Over a 5-year period, 108 patients with ALL were treated (66 with the Hyper-CVAD regimen, and 42 with the CALGB 8811 regimen). Median age at diagnosis was 33 years, with 63% males. The most common immunophenotype was CD10-positive common ALL, and 16% have BCR-ABL translocation. Complete response (CR) rate was 88%. After a median follow-up of 32 months (range, 10-72 months), the median survival (MS) was 30 months, and CR duration (CRD) was 28 months. In the multivariate analysis, the presence of BCR-ABL translocation was the only poor prognostic factor with lower MS of 23 months (p<0.01). There was no difference in MS or CRD between the two used regimens.

Conclusion: International protocols for adult ALL were successfully applied to our patients. There is no difference in efficacy between Hyper-CVAD and CALGB 8811 regimens. Future protocols for adult ALL should incorporate new targeted agents and minimal residual disease monitoring to improve outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve for complete response duration of acute lymphoblastic leukemia patients treated with either Hyper-CVAD or CALGB 8811 regimens.
Figure 2
Figure 2
Kaplan-Meier curve for survival of acute lymphoblastic leukemia patients treated with either Hyper-CVAD or CALGB 8811 regimens
See this image and copyright information in PMC

References

    1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030–1043. doi: 10.1016/S0140-6736(08)60457-2. - DOI - PubMed
    1. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113:1408–1411. doi: 10.1182/blood-2008-06-164863. - DOI - PubMed
    1. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8:994–1004. - PubMed
    1. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123–131. - PubMed
    1. Bassan R, Hoelzer D. Modern Therapy of Acute Lymphoblastic Leukemia. J Clin Oncol. 2011;29:532–543. doi: 10.1200/JCO.2010.30.1382. - DOI - PubMed

LinkOut - more resources